Ontvang nu dagelijks onze kooptips!

word abonnee
Van beleggers
voor beleggers
desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?

Aandeel Galapagos AEX:GLPG.NL, BE0003818359

Laatste koers (eur) Verschil Volume
26,380   -0,540   (-2,01%) Dagrange 26,360 - 27,140 178.602   Gem. (3M) 99K

Galapagos mei 2019

2.893 Posts
Pagina: «« 1 ... 95 96 97 98 99 ... 145 »» | Laatste | Omlaag ↓
  1. HansGarrincha 21 mei 2019 20:18
    seekingalpha.com/news/3465778-lillys-...

    New data from a Phase 2 clinical trial, SERENITY, evaluating Eli Lilly's (LLY +0.4%) mirikizumab in patients with moderately to severely active Crohn's disease (CD) showed a treatment benefit. The results were presented at Digestive Disease Week in San Diego.

    The primary endpoint was the proportion of patients achieving at least a 50% reduction from baseline in a scale called SES-CD at week 12.

    The proportions of patients receiving 200 mg, 600 mg or 1,000 mg of mirikizumab achieving the targeted reduction in SES-CD were 25.8%, 37.5% and 43.8%, respectively, compared to 10.9% for placebo. The proportions of patients achieving endoscopic remission were 6.5%, 15.6% and 20.2%, respectively, versus 1.6% in the control group.

    On the safety front, 64% of treated patients reported one or more drug-related adverse events during the induction phase of the study. The most common were headache, weight gain and nasopharyngitis. Five reported one or more serious adverse events.

    The maintenance phase of the trial is ongoing.

    Mirikizumab is a monoclonal antibody that binds to the p19 subunit of the proinflammatory cytokine interleukin 23 (IL-23).
2.893 Posts
Pagina: «« 1 ... 95 96 97 98 99 ... 145 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.